Momenta Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Momenta Pharmaceuticals Inc (MNTA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Momenta Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 30M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-12.1% annualized vs trailing 12 months).
- Peer revenue share: Momenta Pharmaceuticals Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MNTA Sales vs. its Competitors, Q2 2020
Momenta Pharmaceuticals Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.4% year over year, combined, vs 27.6% for Momenta Pharmaceuticals Inc. Momenta Pharmaceuticals Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Momenta Pharmaceuticals Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Momenta Pharmaceuticals inc | - | No | No | No |
| High-Confidence Competitors (133) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MNTA Stock Performance relative to its Competitors
MNTA Stock Performance relative to High-Confidence Competitors
Momenta Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Momenta Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medtronic plc | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Angiodynamics Inc | Company report | 85% |
| Intuitive Surgical Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Encision Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| United Health Products Inc | Company report | 85% |
| Co diagnostics Inc | Company report | 85% |
| Catheter Precision Inc | Company report | 85% |
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Globus Medical Inc | Company report | 85% |
| Bioventus Inc | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Acutus Medical Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Cardiovascular Systems, Inc. | Company report | 85% |
| Inspiremd Inc | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Enovis Corp | Company report | 85% |
| Biodexa Pharmaceuticals Plc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Stryker Corp | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Paragon 28 inc | Company report | 85% |
| Monogram technologies inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Addex Therapeutics Ltd | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Apexigen Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Bone Biologics Corporation | Company report | 85% |
| The Cooper Companies Inc | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Lenz Therapeutics Inc | Company report | 85% |
| Spyglass Pharma Inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Starco Brands Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Immix Biopharma Inc | Company report | 85% |
| Vor Biopharma Inc | Company report | 85% |
| Xtant Medical Holdings Inc | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Arrivent Biopharma inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Nanobiotix S a | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Sintx Technologies Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Ss Innovations International Inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| Gh Research Plc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Compass Pathways Plc | Company report | 85% |
| Cytosorbents Corporation | Company report | 85% |
| Nexgel Inc | Company report | 85% |
| Alpha Pro Tech Ltd | Company report | 85% |
| Pulse Biosciences Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Medinotec Inc | Company report | 85% |
| BSGM | Company report | 85% |
| NAYA | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Alkermes | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Otsuka Pharmaceutical | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Streamex Corp | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| INVO | Company report | 85% |
| Evolus Inc | Company report | 85% |
| MNMD | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Philips N.V. | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Altamira Therapeutics Ltd | Company report | 85% |
| ENTO | Company report | 85% |
| Mira Pharmaceuticals Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Xoma Royalty Corporation | Company report | 85% |
| Church and Dwight Co Inc | Company report | 85% |
| Prestige Consumer Healthcare Inc | Company report | 85% |
| The Hain Celestial Group Inc | Company report | 85% |
| Absci Corp | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Glucotrack Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| The Honest Company Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Assembly Biosciences Inc | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Staar Surgical Co | Company report | 85% |
| Inmune Bio Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Inflarx N V | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Allergan | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Aytu Biopharma Inc | Company report | 85% |
| Sunovion | Company report | 85% |
| Alphatec Holdings Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Lyra Therapeutics Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Zevra Therapeutics Inc | Company report | 85% |
| 4d Molecular Therapeutics Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Reshape Lifesciences Inc | Company report | 85% |
| Inovio Pharmaceuticals Inc | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Relmada Therapeutics Inc | Company report | 85% |
| Atricure Inc | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Livanova Plc | Company report | 85% |
| Cvrx inc | Company report | 85% |
| Ir med Inc | Company report | 85% |
| Adagio Medical Holdings inc | Company report | 85% |
| Meihua International Medical Technologies Co Ltd | Company report | 85% |
| Surmodics Inc | Company report | 85% |
| Transmedics Group Inc | Company report | 85% |
| Silk Road Medical Inc | Company report | 85% |
| Axogen inc | Company report | 85% |
| Penumbra Inc | Company report | 85% |
| Artivion Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Si bone inc | Company report | 85% |
| Irhythm Holdings Inc | Company report | 85% |
| Non Invasive Monitoring Systems Inc | Company report | 85% |
| Danaher Corporation | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Smith and Nephew Plc | Company report | 85% |
| Bausch and Lomb Corp | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Conmed Corporation | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Surgalign Holdings Inc | Company report | 85% |
| Pacira Biosciences inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Establishment Labs Holdings Inc | Company report | 85% |
| Nuvasive Inc | Company report | 85% |
| Unilever Plc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Orchestra Biomed Holdings Inc | Company report | 85% |
| Merit Medical Systems Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Atrion Corporation | Company report | 85% |
| Sanofi | Company report | 85% |
| Lemaitre Vascular Inc | Company report | 85% |
| Procter and Gamble Co | Company report | 85% |
| Inari Medical Inc | Company report | 85% |
| Semler Scientific inc | Company report | 85% |
| Biohaven Ltd | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Alexion Pharmaceuticals Inc | Company report | 85% |
| Teleflex Incorporated | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Est e Lauder Companies Inc | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Vicarious Surgical Inc | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Axsome Therapeutics Inc | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Becton Dickinson And Company | Company report | 85% |
| Zimvie Inc | Company report | 85% |
| 3m Company | Company report | 85% |
| Aptinyx Inc | Company report | 85% |
| Stereotaxis Inc | Company report | 85% |
| Insulet Corporation | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Inspire Medical Systems inc | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Colgate palmolive Company | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Asensus Surgical Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Cerevel Therapeutics Holdings Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Zimmer Biomet Holdings Inc | Company report | 85% |
| Alcon inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Journey Medical Corp | Company report | 85% |
| Karuna Therapeutics Inc | Company report | 85% |
| Cervomed Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Conformis inc | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Minerva Neurosciences Inc | Company report | 85% |
| Organon and Co | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
Company report basis, confidence, active dates and source counts for Momenta Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
